Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis.
The trial will enroll some 120 patients to assess the efficacy and safety of reproxalap compared with a vehicle control group. The primary endpoint will be subject-reported ocular itching score.
“Standard of care antihistamines are ineffective in nearly a quarter of all allergic conjunctivitis patients, many of whom require adjunct therapy, including corticosteroids, which cannot be used chronically due to toxicity,” Dr. Todd Brady, Aldeyra’s president and CEO, said in a statement.
“We believe that reproxalap may offer a durable and highly differentiated approach for the treatment of ocular allergy, a condition that is increasing in prevalence but has not benefited from the introduction of a novel therapeutic approach in decades,” he added.
